Financial Counselors Inc. Raises Holdings in Stryker Co. (NYSE:SYK)

Financial Counselors Inc. grew its holdings in Stryker Co. (NYSE:SYK) by 4.3% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 38,370 shares of the medical technology company’s stock after buying an additional 1,593 shares during the quarter. Financial Counselors Inc.’s holdings in Stryker were worth $13,862,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Wealth Enhancement Advisory Services LLC lifted its holdings in Stryker by 78.9% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 133,020 shares of the medical technology company’s stock worth $45,260,000 after buying an additional 58,673 shares during the period. OFI Invest Asset Management lifted its holdings in Stryker by 3,210.9% in the 2nd quarter. OFI Invest Asset Management now owns 3,344 shares of the medical technology company’s stock worth $1,062,000 after buying an additional 3,243 shares during the period. Envestnet Asset Management Inc. lifted its holdings in Stryker by 2.7% in the 2nd quarter. Envestnet Asset Management Inc. now owns 618,041 shares of the medical technology company’s stock worth $210,289,000 after buying an additional 16,504 shares during the period. Sivik Global Healthcare LLC lifted its holdings in Stryker by 8.0% in the 3rd quarter. Sivik Global Healthcare LLC now owns 27,000 shares of the medical technology company’s stock worth $9,754,000 after buying an additional 2,000 shares during the period. Finally, Fiera Capital Corp lifted its holdings in Stryker by 42.1% in the 2nd quarter. Fiera Capital Corp now owns 16,713 shares of the medical technology company’s stock worth $5,687,000 after buying an additional 4,948 shares during the period. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on SYK. StockNews.com lowered Stryker from a “buy” rating to a “hold” rating in a research report on Friday, November 22nd. UBS Group increased their target price on Stryker from $366.00 to $370.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 30th. Citigroup increased their target price on Stryker from $406.00 to $411.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Canaccord Genuity Group increased their target price on Stryker from $360.00 to $400.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Finally, Wolfe Research began coverage on Stryker in a research report on Tuesday, September 10th. They issued an “outperform” rating and a $405.00 target price for the company. Five equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to data from MarketBeat.com, Stryker currently has a consensus rating of “Moderate Buy” and an average price target of $393.65.

Insider Buying and Selling at Stryker

In other news, VP M Kathryn Fink sold 7,347 shares of the firm’s stock in a transaction on Tuesday, September 17th. The stock was sold at an average price of $366.98, for a total value of $2,696,202.06. Following the transaction, the vice president now directly owns 10,042 shares in the company, valued at $3,685,213.16. This trade represents a 42.25 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Kevin Lobo sold 57,313 shares of the firm’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the transaction, the chief executive officer now owns 100,027 shares in the company, valued at approximately $36,879,954.90. This trade represents a 36.43 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 66,781 shares of company stock worth $24,612,275. Insiders own 5.90% of the company’s stock.

Stryker Stock Performance

Shares of SYK opened at $388.14 on Friday. The business’s fifty day simple moving average is $367.97 and its two-hundred day simple moving average is $350.94. The company has a current ratio of 1.91, a quick ratio of 1.22 and a debt-to-equity ratio of 0.66. Stryker Co. has a 12 month low of $285.79 and a 12 month high of $398.20. The company has a market cap of $147.97 billion, a price-to-earnings ratio of 41.60, a P/E/G ratio of 2.93 and a beta of 0.91.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, beating the consensus estimate of $2.77 by $0.10. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The business had revenue of $5.49 billion for the quarter, compared to the consensus estimate of $5.37 billion. During the same period last year, the business posted $2.46 EPS. The company’s revenue was up 11.9% compared to the same quarter last year. Research analysts anticipate that Stryker Co. will post 12.06 earnings per share for the current fiscal year.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.